

GENETEC TECHNOLOGY BERHAD Company No.:199701030038 (445537-W) (Incorporated in Malaysia)

Interim Report for the

Fifth Quarter Ended

30 June 2024

Contents

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	1
Condensed Consolidated Statement of Financial Position	2
Condensed Consolidated Statement of Changes in Equity	3
Condensed Consolidated Statement of Cash Flows	4
Notes to the Interim Financial Report	5 - 12

The figures have not been audited

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	<u>Note</u>	Current Year Quarter 30/06/2024 RM'000	Current Year 15 months ended 30/06/2024 RM'000
Revenue Cost of sales	_	51,486 (41,358)	347,003 (238,171)
Gross Profit		10,128	108,832
Interest income Other operating income Administrative expenses Other operating expenses	_	2,198 (462) (4,152) (682)	2,889 7,857 (20,884) (4,828)
Profit from operations Finance costs Net (loss)/gain on financial assets and financial liabilities at fair value Share of loss of joint venture		7,030 (23) 624 -	93,866 (3,106) (120) (250)
Profit before taxation Taxation		7,631 168	90,390 (5,841)
Profit for the financial period	=	7,799	84,549
Other comprehensive income Foreign currency translation differences of foreign operations	_	2	(452)
Total comprehensive income for the financial period	_	7,801	84,097
Profit attributable to: Equity holders of the parent Non-controlling interest Profit for the financial period	_	10,158 (2,359) 7,799	86,123 (1,574) 84,549
	=		
Total comprehensive income attributable to: Equity holders of the parent Non-controlling interest	_	10,341 (2,540)	85,852 (1,755)
Total comprehensive income for the financial period		7,801	84,097
Earnings per share (sen):-	= 24		
(a) Basic (b) Diluted	=	1.32 1.31	11.19 11.07

Due to the change in the current financial year end from 31 March to 30 June, there were no comparative financial information available for the 15 months financial period ended 30 June 2024.

The Condensed Consolidated Statement of Comprehensice Income should be read in conjunction with the Audited Financial Statements for the financial year ended 31 March 2023 and the accompanying explanatory notes attached to the interim financial statements.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	Note	(Unaudited) As at end of current quarter 30/06/2024 RM'000	(Audited) As at preceding financial year ended 31/03/2023 RM'000
ASSETS			
Non-current assets			
Property, plant and equipment		134,793	114,183
Intangible assets Investment in joint venture		5,060	5,060 1
Deferred tax assets		3,273	2,647
Other investment		2,280	-
		145,406	121,891
Current assets			
Inventories		13,795	16,800
Derivative financial assets Trade receivables	21	- 43,589	175 119,169
Current tax assets		114	266
Other receivables		14,394	14,386
Contract assets Short-term investment		186,257 122,815	48,068 147,120
Cash and bank balances		41,340	32,672
		422,304	378,656
TOTAL ASSETS		567,710	500,547
EQUITY AND LIABILITIES			
Share capital		269,980	266,207
Reserves		219,174	130,761
Equity attributable to equity holders	s of the parent	489,154	396,968
Non-controlling interest		7,574	9,329
Total equity		496,728	406,297
Non-current liabilities			
Borrowings	20	3,954	4,496
Hire purchase liabilities	20	4,461	3,644
Lease liabilities Deferred tax liabilitity		83	94 806
2		8,841	9,040
• ····		·	,
Current liabilities Borrowings	20	10,850	45,432
Hire purchase liabilities	20	3,213	1,670
Lease liabilities		145	173
Current tax liabilities Derivative financial liabilities	21	610 120	360
Contract liabilities		1,135	1,060
Trade payables Other payables		36,602 9,466	29,007 7,508
Calor payables		62,141	85,210
TOTAL EQUITY AND LIABILITIES		567,710	500,547
Net assets per share (RM)*		0.63	0.53

Note:

* Net assets per share attributable to shareholders of the Company : Equity attributable to equity holders of the parent /Number of issued shares

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 31 March 2023 and the accompanying explanatory notes attached to the interim financial statements.

The figures have not been audited

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	-	Nor Distribu		Distributable			
	Share Capital RM'000	Share Option Reserve RM'000	Translation Reserve RM'000	Retained Profits RM'000	Total RM'000	Non-controlling interest RM'000	Total equity RM'000
15 months ended 30 June 2024							
Balance at 1 April 2023	266,207	1,125	(1,571)	131,207	396,968	9,329	406,297
Prior year adjustment	-	-	-	3,420	3,420	-	3,420
Foreign currency translation	-	-	(271)	-	(271)	(181)	(452)
Share options exercised	3,773	(859)	-	-	2,914	-	2,914
Profit for the financial year	-	-	-	86,123	86,123	(1,574)	84,549
Balance at 30 June 2024	269,980	266	(1,842)	220,750	489,154	7,574	496,728
<u>12 months ended 31 March 2023</u>							

Balance at 1 April 2022	88,215	1,125	(1,319)	64,574	152,595	8,200	160,795
Foreign currency translation	-	-	(252)	-	(252)	(125)	(377)
Issuance of ordinary shares	177,992	-	-	-	177,992	-	177,992
Profit for the financial year	-	-	-	66,633	66,633	1,254	67,887
Balance at 31 March 2023	266,207	1,125	(1,571)	131,207	396,968	9,329	406,297

The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 31 March 2023 and the accompanying explanatory notes attached to the interim financial statements.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS	(1	
	(Unaudited) 15 months ended 30/06/2024 RM'000	(Audited) 12 months ended 31/03/2023 RM'000
Operating Activities Profit before taxation	90,390	74,900
Adjustments for:		
Depreciation of property, plant and equipment Gain on disposal of property, plant and equipment Property, plant and equipment written off Interest costs	8,026 (24) - 3,106	3,780 (15) 6 3,501
Interest income Change in fair value of short-term investment	(2,889) (3,811)	(303) (888)
Unrealised derivative loss/(gain) Unrealised foreign exchange (gain)/loss Write-down of inventories	120 (321) 358	(175) 106 169
Share of loss of joint venture	250	-
Operating profit before changes in working capital	95,205	81,081
Changes in working capital Inventories	(5,571)	29,522
Trade and other receivables	76,143	31,651
Contract assets/liabilities	(125,397)	(46,508)
Trade and other payables	9,478	2,601
Net cash generated from operating activities Income tax paid	49,858 (7,607)	98,347 (5,993)
Net cash generated from operating activities	42,251	92,354
Investing Activities		
Interest received	2,889	303
Fair value gain on short-term investment Investment in joint venture	3,811 (249)	888 (1)
Proceeds from disposal of property, plant and equipment	24	99
Purchase of property, plant and equipment Acquisition of other investment	(22,390) (2,280)	(74,674) -
Net cash generated used in investing activities	(18,195)	(73,385)
Financing Activities		
Proceeds from issuance of shares	2,914	177,992
Net repayment of trade finance liabilities	(34,279)	(42,129)
Net repayment of term loan Net drawdown of hire purchase liabilities	(1,106) (3,623)	(1,498) (1,388)
Payment of lease liabilities	(302)	(1,000)
Interest paid	(3,106)	(3,501)
Net cash (used in)/generated from financing activities	(39,502)	129,242
Net change in cash and cash equivalents	(15,446)	148,211
Effect of exchange rate changes	(452)	(377)
Cash and cash equivalents at beginning of year	179,792	31,958
Cash and cash equivalents at end of period/year	163,894	179,792
Cash and cash equivalent comprise of:-		
Cash and bank balances	11 210	30 670
Short-term investment	41,340 122,815	32,672 147,120
	164,155	179,792
Less: Bank overdraft	(261)	-
Cash and cash equivalents	163,894	179,792

The Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 31 March 2023 and the accompanying explanatory notes attached to the interim financial statements.

NOTES TO THE INTERIM FINANCIAL REPORT

The figures have not been audited

1. BASIS OF PREPARATION

The interim financial report has been prepared in accordance with the requirements of the Malaysia Financial Reporting Standard ("MFRS"), MFRS 134: Interim Financial Reporting and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the Main Market.

The interim financial report should be read in conjunction with the audited financial statements of Genetec Technology Berhad ("Genetec" or the "Company") for the financial year ended 31 March 2023. These explanatory notes attached to the interim financial report provides an explanation of the events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 March 2023.

The significant accounting policies and methods of computation adopted by Genetec and its subsidiary companies ("Genetec Group " or the "Group") in this interim financial report are consistent with those adopted in the financial statements for the financial year ended 31 March 2023.

During the financial period, the Group has adopted the following accounting standards, interpretations and amendments of the MFRSs that have become effective in current financial period:-

MFRSs and/or IC Interpretations (Including The Consequential Amendments)

MFRS 17 Insurance Contracts

Amendments to MFRS 17 Insurance Contracts

Amendment to MFRS 17: Initial Application of MFRS 17 and MFRS 9 - Comparative

Information

Amendments to MFRS 101: Disclosure of Accounting Policies

Amendments to MFRS 108: Definition of Accounting Estimates

Amendments to MFRS 112: Deferred Tax related to Assets and Liabilities arising from a Single

Transaction

Amendments to MFRS 112: International Tax Reform - Pillar Two Model Rules

The initial application of the abovementioned accounting standards, interpretations or amendments did not have any material financial impact to the current period and prior period financial statements of the Group.

The Group has not applied in advance the following MFRSs, interpretations and amendments that have been issued by the Malaysian Accounting Standard Board ("MASB") but are not yet effective for the current financial period:-

MFRSs and/or IC Interpretations (Including The Consequential Amendments)

	Effective Date
MFRS 18 Presentation and Disclosure in Financial Statements	1 January 2027
MFRS 19 Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and	
Measurement of Financial Instruments	1 January 2026

Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets	
between an Investor and its Associate or Joint Venture	Deferred
Amendments to MFRS 16: Lease Liability in a Sale and Leaseback	1 January 2024
Amendments to MFRS 101: Classification of Liabilities as Current or	
Non-current	1 January 2024
Amendments to MFRS 101: Non-current Liabilities with Covenants	1 January 2024
Amendments to MFRS 107 and MFRS 7: Supplier Finance Arrangements	1 January 2024
Amendments to MFRS 121: Lack of Exchangeability	1 January 2025

The adoption of the abovementioned accounting standards, interpretations or amendments is expected to have no material financial impact to the current period and prior period financial statements of the Group upon their initial application.

2. AUDIT REPORT OF THE PRECEDING ANNUAL FINANCIAL STATEMENTS

There was no audit qualification on the annual financial statements of the Company and its subsidiaries for the financial year ended 31 March 2023.

3. SEASONALITY OR CYCLICALITY OF INTERIM OPERATIONS

The business of the Group is not affected by any significant seasonal or cyclical factors for the current quarter under review.

4. UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

During the current quarter under review, there was no item or event, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

5. MATERIAL CHANGE IN ESTIMATES

There was no material change in the nature and amount of estimates reported that may have a material effect on the results for the current quarter under review.

6. ISSUANCES, CANCELLATIONS, REPURCHASES, RESALE AND REPAYMENTS OF DEBT AND EQUITY SECURITIES

There were no issues, cancellation, repurchase, resale or repayments of debt and equity securities for the period ended 30 June 2024, except for below:

Employees' Share Option Scheme ("ESOS")

During the current quarter under review, the company issued 1,520,000 new ordinary shares of RM0.11 per share pursuant to the Employees' Share Option Scheme.

7. DIVIDEND PAID

No dividend was paid during the current quarter under review.

8. SEGMENT INFORMATION

Business segment information is not presented as the Group is primarily engaged in one business segment which is designing and building of smart automation systems, customised factory automated equipment and integrated systems from conceptual design, development of prototype to mass replication of equipment.

9. PROPERTY, PLANT AND EQUIPMENT

There was no revaluation on any of the Group's property, plant and equipment during the current quarter under review.

10. MATERIAL EVENTS SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There is no material event affecting the Group subsequent to the current quarter under review.

11. CHANGES IN THE COMPOSITION OF THE GROUP

There were no material changes in the composition of the Group for the current quarter under review.

12. CONTINGENT LIABILITIES OR CONTINGENT ASSETS

There was no contingent liabilities or contingent assets as at 30 June 2024 and up to the date of this report.

13. CAPITAL COMMITMENTS

The capital commitment as at 30 June 2024 are as follows:

	RM'000
Property, plant and equipment	
Authorised but not contracted for	25,349

14. **REVIEW OF PERFORMANCE**

The Group has changed its financial year end from 31 March 2024 to 30 June 2024. This reporting covers the 15 months financial period from 1 April 2023 to 30 June 2024. As such, there are no comparative information presented in this report.

For the current quarter ended 30 June 2024, the Group recorded a revenue of RM51.5 million and profit before taxation of RM7.6 million.

For the 15 months financial period ended 30 June 2024, the Group recorded revenue of RM347.0 million and profit before taxation of RM90.4 million.

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

Revenue of the Group decreased by RM19.0 million or 27.0% to RM51.5 million for the current quarter under review as compared to RM70.5 million recorded in the preceding quarter ended 31 March 2024.

The Group recorded a profit before taxation of RM7.6 million, a decrease of RM11.5 million or 60.2% as compared to a profit before taxation of RM19.1 million for the immediate preceding quarter. The decrease in profit before taxation was mainly due to lower revenue recorded.

16. PROSPECT

For the financial period under review, the Group continues to deliver stable performance in a high-interest rate environment and against a moderately soft economic backdrop worldwide. The Group remains positive but is cautious as we see major industry players in the automotive industry taking the monitoring approach, primarily caused by policy uncertainty as a result of the U.S. Presidential election coming November 2024, macroeconomic uncertainties including inflation and interest rates policies and global geopolitical environment. The Group expect more certainty in the industry after the U.S. Presidential Election.

As a business, Genetec has weathered various economic cycles since its inception in 1997 and have always come out stronger. Under the current business environment, our team continues to be on the ground in our client's facilities, busy supporting our clients with their improvement initiatives and new developments, as our clients focuses on improving yields for long term production efficiency. As a pioneer in specialised automated assembly line manufacturer, our team is working closely with our clients on conceptualising the manufacturing process, to automate most of the currently labour-intensive processes. We see huge opportunity when our clients start to ramp up production to meet demand. Further, retaining and growing our share of wallet with long-term clients has and continues to remain a priority as we look for opportunity to broaden our product offering.

At the same time, it remains the Group's strategy to broaden our clientele base and product offering. We are always in the lookout for new opportunities in new industries and new markets.

The Group continues to focus on retaining talent – to retain the experience and technical expertise of our people. The Group recognises that Genetec's strength lies with our people and we take this seriously as the Group continue to invest in our people - to train, retain, and reward our team.

17. VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

Not applicable as Genetec has not issued any profit forecast or profit guarantee in a public document.

18. TAXATION

Current tax: -	Current Year Quarter 30.06.2024 RM' 000	Current Year 15 Months Ended 30.06.2024 RM' 000
- current year	(1,008)	(7,008)
- overprovision in prior year	87	78
Deferred tax: -		
- current year	674	674
- overprovision in prior year	415	415
	168	(5,841)

The effective tax rate of the Group for the financial period ended 30 June 2024 was lower than the statutory tax rate due to availability of pioneer status tax incentive.

19. STATUS OF CORPORATE PROPOSAL

Private Placement

On behalf of the Company's Board of Directors, CIMB Investment Bank Berhad ("CIMB") had on 12 January 2023 announced that the Company proposed to undertake a private placement exercise involving the issuance of up to 71,669,520 new ordinary shares ("Proposed Private Placement").

Bursa had vide its letter dated 31 January 2023 approved the listing and quotation of up to 71,669,520 new ordinary shares in the Company to be issued pursuant to the Proposed Private Placement. The Company has fixed the issue price for the Private Placement comprising 68,196,180 Placement Shares at RM2.61 on 31 January 2023.

On behalf of the Company's Board of Directors, CIMB had on 15 February 2023 announced the completion of the Proposed Private Placement with the listing and quotation of 68,196,180 new ordinary shares on the ACE Market.

At the date of this report, the proposed and actual utilisation of RM178 million proceeds raised from the issuance for a total of 68,196,180 new ordinary shares at issue price per placement share of RM2.61 pursuant to the Private Placement are as follows:-

	Proposed Utilisation	Actual Utilisation	Available for Utilisation	Expected Utilisation Time Frame
	RM'000	RM'000	RM'000	
Expansion of manufacturing facilities	94,000	80,228	13,772	Within 36 months
Working capital requirements	80,992	64,020	16,972	Within 24 months
Estimated Expenses in relation to the Private Placement	3,000	3,000	-	Within 1 month
	177,992	147,248	30,744	

Long-Term Incentive Plan ("Proposed LTIP")

On behalf of the Company's Board of Directors, KAF Investment Bank Berhad ("KAF IB") had on 28 May 2024 announced that the Company proposed to establish and implement a proposed LTIP in the form of an employees' share grant scheme of up to 5% of the Company's total issued shares (excluding treasury shares, if any) at any point of time during the duration of the LTIP for the eligible executive directors and employees of Genetec and its subsidiary companies (excluding subsidiaries which are dormant) who fulfill the eligibility criteria.

Bursa Securities had, vide its letter dated 12 July 2024, resolved to approve the listing of such number of new shares, representing up to 5% of the total number of issued shares of the Company (excluding treasury shares, if any) to be issued pursuant to the Proposed LTIP subject to the following conditions:

- 1. KAF IB and the Company must fully comply with the relevant provisions under the Listing Requirements pertaining to the implementation of the Proposed LTIP;
- 2. KAF IB is required to submit a confirmation to Bursa Securities of full compliance of the Proposed LTIP pursuant to paragraph 6.43(1) of the Listing Requirements and stating the effective date of implementation together with a certified true copy of the resolution passed by the shareholders in general meeting approving the Proposed LTIP; and

3. The Company is required to furnish Bursa Securities on a quarterly basis a summary of the total number of Shares listed pursuant to the Proposed LTIP as at the end of each quarter together with a detailed computation of listing fees payable.

On 29 August 2024, the Company's Board of Directors announced that the poll results of the resolutions pertaining to the Proposed LTIP are detailed as below at the Extraordinary General Meeting held on the same day:

Resolution	Descriptions	Results
1	To Approve Proposed Establishment Of A Long-Term Incentive Plan In The Form Of An Employees' Share Grant Scheme For The Eligible Directors And Employees Of Genetec And Its Subsidiaries (Excluding Dormant Subsidiaries) And Waiver Of Pre-Emptive Rights To New Shares Under Section 85(1) Of The Companies Act 2016 ("Act") Read Together With Clause 63 Of The Constitution Of The Company	Accepted
2	To Approve Proposed Allocation Of The Grants To The Executive Directors Of Genetec Pursuant To The Proposed LTIP - Chin Kem Weng	Rejected
3	To Approve Proposed Allocation Of The Grants To The Executive Directors Of Genetec Pursuant To The Proposed LTIP – Sow Ewe Lee	Accepted

20. BORROWINGS

Details of the Group's borrowings as at 30 June 2024 are as follows:-

Current	RM'000
Unsecured: Hire purchase Secured: Term Ioan Trade bills Bank overdraft	3,213 878 9,711 <u>261</u> 14,063

Non-current	RM'000
Unsecured: Hire purchase	4,461
Secured: Term loan	3,954
	8,415

21. FINANCIAL INSTRUMENTS

Derivatives

As at 30 June 2024, the foreign currency forward contracts which have been entered into by the Group to hedge against foreign trade receivable are as follows:-

Forward Foreign Currency Contracts	Contract Value	Fair Value	Difference
	(RM'000)	(RM'000)	(RM'000)
US Dollar - Less than 1 year	18,758	18,878	120

All derivative financial instruments held by the Group will be recognised as assets or liabilities in the balance sheet, and will be classified as financial assets or financial liabilities at fair value through profit and loss. When derivative financial instruments are recognised initially, they are measured at fair value. Any gain or loss from changes in fair value of the derivatives financial instruments will be recognised as profit or loss.

There is no change to the Group's financial risk management policies in managing these derivatives, its related accounting policies and the market risk associated with these derivatives since the last financial year.

22. MATERIAL LITIGATIONS

As at the date of this report, neither the Company nor its subsidiaries is engaged in any litigation or arbitration, either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiaries and the Board of Directors does not know of any proceedings pending or threatened, or of any fact likely to give rise to any proceedings, which might materially and adversely affect the position or business of the Company or its subsidiaries.

23. DIVIDEND PAYABLE

In respect of the financial period ended 30 June 2024, the Company's Board of Directors had on 29 August 2024 declared an interim single-tier dividend of 2.0 sen per ordinary share, the Entitlement Date and Payment Date will be on 13 September 2024 and 4 October 2024, respectively. This dividend has not been reflected in the financial statements for the current financial period under review but it will be accounted for in shareholders' equity as an appropriation of retained profits in the next quarter ending 30 September 2024.

24. EARNINGS PER SHARE

Basic earnings per share	Current Year Quarter 30.06.2024 RM' 000	Current Year 15 Months Ended 30.06.2024 RM' 000
Net Profit attributable to equity holders of the parent	10,158	86,123
Weighted average number of ordinary shares in issue ('000)	769,946	769,946
Basic EPS (sen)	1.32	11.19

Diluted earnings per share	Current Year Quarter 30.06.2024 RM' 000	Current Year 15 Months Ended 30.06.2024 RM' 000
Net Profit attributable to equity holders of the parent	10,158	86,123
Weighted average number of ordinary shares in issue ('000)	769,946	769,946
Effect of dilution: Exercise of ESOS	7,808	7,808
Adjusted weighted average number of shares in issue ('000)	777,754	777,754
Diluted EPS (sen)	1.31	11.07

25. PROFIT BEFORE TAXATION

Profit before taxation is arrived after	Current Year Quarter 30.06.2024 RM' 000	Current Year 15 Months Ended 30.06.2024 RM' 000
charging/(crediting):		
Depreciation of property, plant and equipment	934	8,026
Fair value gain on other investments	811	(3,811)
Gain on disposal of property, plant and equipment	-	(24)
Net derivatives loss/(gain):		
- Realised	674	4,820
- Unrealised	(624)	120
Net foreign exchange gain:		
- Realised	(223)	(2,835)
- Unrealised	(83)	(321)
Write-down of inventories	358	358
Interest income	(2,198)	(2,889)
Interest expense	23	3,106